StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) income statement

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.00−0.24 (-1.81%)

Close on Nov 20, 2026Market cap $861.89MP/E –Yield 0.00%

Latigo Biotherapeutics, Inc. financial ratios

See a number that looks wrong?